Neurol Med Chir (Tokyo) 60, 337-350, 2020

Online June 12, 2020

Japanese National Questionnaire Survey in 2018 on Complications Related to Cranial Implants in Neurosurgery

Takao YASUHARA,¹ Satoshi MURAI,¹ Nobuhiro MIKUNI,² Susumu MIYAMOTO,³ and Isao DATE¹

¹Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama, Japan ²Department of Neurosurgery, Sapporo Medical University, Sapporo, Hokkaido, Japan ³Department of Neurosurgery, Kyoto University, Kyoto, Kyoto, Japan

Abstract

Cranial implants are commonly used throughout the world, yet the data on complications remain partly clarified. The aim of this study was to gather real data in 2018 on complications related to cranial implants in neurosurgery. The survey population consisted of 1103 institutes supplying neurosurgical treatment. The survey consisted of two-stage questionnaire. First the incidence of complications was investigated, then the secondary questionnaire was e-mailed to the respondents about the detailed of the complications. As the result, the annual incidence of complications related to cranial implants was 0.558% in Japan. Titanium plate and mesh were used predominantly in craniotomy and cranioplasty, respectively. The second survey collected data on 449 cases with complications (infection: 63%, implant exposure: 46%, multiple answer). Postoperative infection was associated with male sex, brain tumor, short interval between surgery and complication, usage of ceramics, hydroxyapatite, resin, and artificial dura, hyponutrition, multiple surgeries, dirty wound, and sinusitis as patient factors, and CSF leakage, ruptured sutures, and sinus maltreatment as surgery factors. Meanwhile, long hospital stay was associated with age, male sex, mRS 3-5 before complication, short interval between initial surgery and complication, large craniotomy, long operative time, usage of ceramics and artificial dura, multiple surgeries and dirty wound as patient factors, ruptured suture as a surgical factor, and bacterial infection, especially MRSA infection, as the complication and treatment consisting of removal as complication factors. In conclusion, this is the first Japanese national survey on complications related to cranial implants in neurosurgery. It is important to recall that complications may arise years after surgery and to be aware of the risk factors associated with complications.

Key words: artificial bone, cranioplasty, infection, re-operation, titanium plate

Introduction

Craniotomy and cranioplasty are standard procedures in neurosurgery, and various cranial implants are widely used for these procedures throughout the world. The titanium plate and screw system was invented and first used for neurosurgery in 1991¹; since then, various other fixation systems, artificial bones and artifacts have been developed and are now commonly used. In most cases, the clinical course after surgery is uneventful; in some cases, however, various complications related to cranial implants, including infections and skin troubles, can arise.²⁾ Some cases require multiple surgeries or tissue reconstruction with vascularized tissue transplantation,^{3,4)} severely burdening patients and their medical teams.

This study reports the results of our national questionnaire survey on complications related to cranial implants in neurosurgery, including the overall complication rate and risk factors for infection and long hospital stay.

Received February 18, 2020; Accepted March 30, 2020

Copyright[©] 2020 by The Japan Neurosurgical Society This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives International License.

Methods

The survey consisted of a two-stage questionnaire on complications related to cranial implants in neurosurgery. The first-stage survey population consisted of 1103 institutes offering neurosurgical treatment. The first stage of the survey was mailed to all of these institutes in October 2018; the second stage was emailed to all institutes that had responded to the first stage with a due date in February 2019. This study was approved by the Institutional Review Board (IRB)/Ethics Committee of Okayama University Hospital, Japan (IRB No. 1808-043). Opt-out informed consent was obtained from patients.

Questionnaire

The questionnaire was in Japanese and consisted of multiple-choice (multiple answers allowed) or written response questions. The first stage collected institutional information on craniotomy and cranioplasty, namely, the number of annual craniotomies; the cranial implants used in craniotomy (titanium plate, titanium mesh, absorbable plate, and others); the cranial implants used in cranioplasty (titanium mesh, ceramics, hydroxyapatite, ultra-high-molecular-weight polyethylene, and others); and the number of cases with complications related to cranial implants.

The second stage collected detailed information on each case in which complications had occurred. Data collected included age at the initial surgery and at complication, neurological ability before complication (modified Rankin scale [mRS]), sex, reason for initial surgery (trauma, aneurysm, tumor, pediatric disease, and others), operative time of initial surgery (hours), craniotomy site (frontotemporal, bifrontal, parietal, occipital, posterior fossa, and others), craniotomy area (cm²), implants used in craniotomy (titanium plate, titanium mesh, absorbable plate, and others) and in cranioplasty (titanium mesh, ceramics, hydroxyapatite, ultra-highmolecular-weight polyethylene, and others), other materials used (artificial dura, dural prosthetics, burr hole cap, bone cement, and others), institute performing the initial surgery (own and other), complications (infection, implant exposure, implant migration, skin depression, and others), infecting organism, cause of complication (Part A, patient factors: sinusitis, cancer, diabetes mellitus, previous irradiation, multiple surgeries, malcirculation, hyponutrition, thin skin, advanced age, dirty wound, others; Part B, surgical factors: ruptured sutures, skin ischemia, cerebrospinal fluid (CSF) leakage, sinus maltreatment, uncovered implant, implant malfixation, others; Part C, device factors: malsterilization, implant breakage, and others), outcome

severity/response level (no treatment, non-surgical treatment, re-operation, aftereffect, and death), treatment method in surgery (system removal, suturing, implant covering, tissue transplantation, and others), involvement of plastic surgeons (plastic surgeons only, combination of plastic surgeons and neurosurgeons, and neurosurgeons only), and length of hospital stay.

Data analyses

Excel sheets were used to summarize the data. Continuous data are shown as mean ± standard deviation. Categorical data are shown as frequency and percentage. Statistical analyses were performed using JMP 13 software (SAS Institute Inc.). The univariate associations between each potential risk factor and the occurrence of infection and hospital stay longer than 30 days were assessed using Pearson's chi-square test or Fisher's exact test, as appropriate. In these assessments, the following rules were applied to identify the risk factors. Diseases were classified into vascular, tumor, traumatic brain injury (TBI) and others (epilepsy, pediatric disease, microvascular decompression, abscess, etc.). Craniotomy site was classified into fronto-temporal, bifrontal, occipital or posterior fossa, and Others (frontal, temporal, etc.). The cutoff points for each continuous variable (age at initial surgery, interval between initial surgery and complication, area of craniotomy, and duration of operation) were determined according to a previous study on analyzing risk factors. Then, we constructed multivariable logistic regression models to estimate the odds ratios (OR) and 95% confidence intervals (CI) of the variables for the development of infection and hospital stay longer than 30 days. We selected clinically relevant variables consistent with the previous reports (age, sex, ADL, types of disease, interval, area of craniotomy, duration of operation, location of craniotomy, devices, and artifacts). Results are presented as OR with 95% CIs. Significance was set at p <0.05.

Results

A flow diagram shows how the cases with complication were included in this study by the two-stage questionnaire survey (Fig. 1).

The first survey

Incidence of complications related to cranial implants

Out of the 1103 institutes to which we sent our first survey, 337 institutes responded (30.6%). Among




Fig. 1 A flow diagram to show cases with complication included in this study.

the responding institutes, 154 reported "no complication related to cranial implants" (45.7%) and 183 reported "or more complications" (54.3%). The total number of annual craniotomies at the responding institutes was 29832. The number of cases with complications related to cranial implants occurring within 5 years was 832. The calculated annual incidence of complications related to cranial implants was 0.558% per year.

Cranial implants used in Japan

For craniotomy, 92.6% of institutes used titanium plate (312/337), 35.9% used titanium mesh (121/337), and 18.4% used absorbable plate (62/337). For cranioplasty, 46.9% of institutes used titanium mesh (158/337), 36.2% used hydroxyapatite (122/337), 33.8% used ceramics (114/337), 25.8% used ultra-high-molecular-weight polyethylene (87/337), 3.3% used resin (11/337), and 2.7% used bone cement (9/337).

The second survey

Out of the 832 cases with complications reported by 183 institutes, details on 449 cases (54.0%) at 68 institutes (37.2%) were obtained in the second survey. These data are shown in Table 1. Age at initial surgery and age at complication were 52.1 ± 0.9 (0–86) and 57.3 ± 0.9 (0–86) years, respectively. The interval between initial surgery and complication was 63.7 ± 4.8 (0–576) months. Neurological ability before complication (mRS) was distributed as follows: mRS0: 123 cases (27.4%), mRS1: 103 cases (22.9%), mRS2: 45 cases (10.0%), mRS3: 52 cases (11.6%), mRS4: 69 cases (15.4%), mRS5: 49 cases (10.9%), and unknown/no response: 8 cases. The distribution of male/female sex was 195/252 (unknown/no response: 2). The reasons for the initial surgery

Neurol Med Chir (Tokyo) 60, July, 2020

were as follows: tumor: 157, aneurysm: 119, trauma: 84, intracerebral hemorrhage: 20, cerebral infarct: 18, moyamoya disease: 13, epilepsy: 9, pediatric neurosurgery: 7, arteriovenous malformation (AVM): 7, others: 12, and unknown/no response: 3. The operative time of initial surgery was 5.6 ± 0.2 (1–17) hours. Distribution of craniotomy sites was as follows: fronto-temporal: 227, bifrontal: 74, parietal: 44, frontal+parietal (+temporal): 36, posterior fossa: 27, occipital: 10, frontal: 9, temporal: 6, others: 14, and unknown/no response: 2. The craniotomy area was 83.3 ± 3.1 (4–900) cm². The implants used in craniotomy were as follows: titanium plate: 314, titanium mesh: 43, absorbable plate: 27, titanium clamp: 8, others: 3, and unknown/no response: 84. The implants used in cranioplasty were as follows: resin: 42, titanium mesh: 40, ceramics: 23, hydroxyapatite: 16, ultra-high-molecular-weight polyethylene: 8, wire: 5, others: 8 (cranioplasty: 139). Other materials used in combination were as follows: artificial dura: 98, bone cement: 23, burr hole cap: 12, shunt/Ommaya reservoir system: 7, dural prosthetics: 5, others: 2. In 392 cases, the initial surgery had been performed at the same institute where the complication was treated; in 54 cases, the initial surgery had been performed at another institute (unknown/no response: 3).

The types of complications were as follows: infection: 281, implant exposure: 205, skin depression: 7, implant migration: 6, others: 10. The infecting organisms were as follows: methicillin-sensitive Staphylococcus aureus (MSSA): 66, methicillinresistant Staphylococcus aureus (MRSA): 64, Enterobacter: 14, methicillin-sensitive Staphylococcus epidermidis: 12, Streptococcus: 10, Corynebacterium: 9, Pseudomonas aeruginosa: 9, Propionibacterium: 7, others: 40, culture negative: 36, and unknown/ no response: 12. The number of cases with concomitant infection was 15. The causes of complication were separately considered as Part A: patient factors, Part B: surgical factors, and Part C: device factors. The patient factors (Part A) were as follows: thin skin: 148, multiple surgeries: 132, advanced age: 57, previous irradiation: 55, cancer: 34, hyponutrition: 32, diabetes mellitus: 29, dirty wound: 27, malcirculation: 25, others: 85, unknown/no response: 80. The surgical factors (Part B) were as follows: uncovered implant: 147, ruptured suture: 31, CSF leakage: 23, sinus maltreatment: 17, skin ischemia: 12, implant malfixation: 9, others: 9, and unknown/no response: 221. Almost no respondents identified any device factors (Part C) (3/449 responses); the device factors that were reported were as follows: malsterilization: 2, implant breakage: 1. The outcome severity/response levels were as follows: re-operation: 439 (dead: 3,

340

 Table 1
 Data of patients with complications related to cranial implants

Factor	Evaluation		Factor	Evaluation	
Age at the initial surgery (y)	52.1 ± 0.9 (0-86)		Implants used in	The number of	
Age at complication (y)	57.3 ± 0.9 (0–86)		cranioplasty	cases	
Duration (months)	63.7 ± 4.8 (0–576)		Resin	42	
mRS	The number of	%	Titanium mesh	40	
	cases		Ceramics	23	
0	123	27.4	Hydroxyapatite	16	
1	103	22.9	Polyethylene	8	
2	45	10.0	Others	13	
3	52	11.6	Materials used in combination	The number of cases	
4	69	15.4	Artificial dura	98	
5	49	10.9	Bone cement	23	
Male/Female	195/252		Burr hole cap	12	
Disease for the initial surgery	The number of cases	%	Shunt/reservoir system	7	
Tumor	157	35.0	Dural prosthetics	5	
Aneurysm	119	26.5	Others	2	
Trauma	84	18.7	Institute of surgery	The number of	%
Intracerebral hemorrhage	20	4.5	performed	cases	, -
Cerebral infarct	18	4.0	Own	392	87.3
Moyamoya disease	13	2.9	Other	54	12.0
Epilepsy	9	2.0	Kind of complications	The number of cases	
Pediatric	7	1.6	Infection	281	
AVM	7	1.6	Implant exposure	205	
Others	12	2.7	Skin depression	7	
Operative time (hours)	5.6 ± 0.2 (1–17)		Implant migration	6	
Area of craniotomy (cm ²)	83.3 ± 3.1 (4–900)		Others	10	
Craniotomy site	The number of cases	%	Infecting organisms	The number of cases	
Fronto-temporal	227	50.6	MSSA	66	
Bifrontal	74	16.5	MRSA		
Parietal	44	9.8	Enterobacter	64	
Frontal+parietal (+T)	36	8.0	MSSE	14	
Posterior fossa	27	6.0		12	
Occipital	10	2.2	Streptococcus	10	
Frontal	9	2.0	Corynebacterium	9	
Temporal	6	1.3	Pseudomonas aeruginosa	9	
Others	14	3.1	Others	40	
Implants used in craniotomy	The number of cases		Cause of complications Part A: patient factor	The number of	
Titanium plate	314			cases	
Titanium mesh	43		Thin skin	148	
Absorbable plate	27		Multiple surgeries	132	
Titanium clamp	8		Aged	57	

Table 1 (Continued)

Factor	Evaluation	
Previous irradiation	55	
Cancer	34	
Hyponutrition	32	
Diabetes mellitus	29	
Dirty wound	27	
Malcirculation	25	
Others	85	
Part B: surgical factor	The number of ca	ses
Uncovered implant	147	
Ruptured suture	31	
CSF leakage	23	
Sinus maltreatment	17	
Skin ischemia	12	
Implant malfixation	9	
Others	12	
Incident level	The number of cases	%
Re-operation	439	97.8
Medication	7	1.6
Treatment methods	The number of cases	%
Removal with suture	352	78.4
Transplantation	32	7.1
Removal with coverage	18	4.0
Others	40	8.9
Involvement of plastic surgeons	The number of cases	
Neurosurgeons only	339	75.5
N + P	94	20.9
Plastic surgeons only	14	3.1
Length of hospital stay (days)	36.9 ± 3.0 (0–910)	

AVM: arteriovenous malformation, MRSA: methicillinresistant *Staphylococcus aureus*, mRS: modified Rankin scale, MSSA: methicillin-sensitive *Staphylococcus aureus*, MSSE: methicillin-sensitive *Staphylococcus epidermidis*. Frontal+parietal(+T): frontal+parietal with/without temporal, N+P: neurosurgeon+plastic surgeon.

aftereffect: 3, non-curative: 2), medication: 7, no treatment: 1, unknown/no response: 2. The surgical treatment methods for complications were as follows: removal with suturing: 352, transplantation: 32, removal with coverage: 18, suturing: 15, medication: 5, others: 20, unknown/no response: 8. The involvement of plastic surgeons was as follows: neurosurgeons only: 339, combination of neurosurgeons and plastic surgeons: 94, plastic surgeons only: 14,

Risk factors for infection

The results of the univariate analyses of factors related to infection in comparison with other complications are summarized in Table 2. The univariate analyses revealed that male sex, tumor as initial disease, interval shorter than 1 month between initial surgery and complication, usage of ceramics, usage of hydroxyapatite, usage of resin, usage of artificial dura, hyponutrition, multiple surgeries, dirty wound, sinusitis, CSF leakage, ruptured suture, and sinus maltreatment were significantly associated with infection. In contrast, vascular disease, bifrontal craniotomy, usage of titanium mesh, usage of burr-hole cap, and thin skin were negatively associated with infection. The results of the multivariate analyses of factors related to infection as a complication are summarized in Table 3. The multivariate analyses revealed that male sex, tumor as initial disease, interval shorter than 1 month between initial surgery and complication, usage of resin, and usage of artificial dura were significantly associated with infection.

Risk factors for hospital stay longer than 30 days

The results of the univariate analyses of factors related to hospital stay longer than 30 days are summarized in Table 4. The univariate analyses revealed that age at initial disease, male sex, mRS, interval shorter than 1 month between initial surgery and complication, craniotomy area more than 100 cm², operative time over 10 hours, usage of ceramics, usage of artificial dura, multiple surgeries, dirty wound, ruptured suture, infection, presence of bacteria, presence of MRSA, and removal as treatment were associated with hospital stay longer than 30 days. The results of the multivariate analyses of factors related to hospital stay longer than 30 days are summarized in Table 5. The multivariate analyses revealed that age at initial disease, male sex, mRS, interval shorter than 1 month between initial surgery and complication, craniotomy area more than 100 cm², operative time over 10 hours, usage of titanium plate, usage of ceramics, and usage of artificial dura were associated with hospital stay longer than 30 days.

Discussion

Key findings

This is the first study revealing the current rates of and factors associated with complications related to cranial implants in neurosurgery in Japan. This

 Table 2
 Univariate analysis for factors associated with infection

	Complications		Univariate		
Factors	Infection Other				
-	n = 168	n = 281	Odds ratio of infection	p value	
Patients' characteristics					
Age at the initial surgery ≤10 years (%)	5 (3.0)	12 (4.3)	1.45 (0.50-4.20)	0.49	
Age at the initial surgery ≥70 years (%)	31 (18.5)	48 (17.1)	0.91 (0.55-1.50)	0.71	
Male sex (%)	51 (30.4)	146 (52.3)	2.51 (1.68-3.77)	<0.001	
mRS 3–5 (%)	58 (34.7)	111 (40.4)	1.27 (0.85-1.90)	0.24	
Disease					
Vascular (%)	85 (51.2)	95 (33.8)	0.49 (0.33-0.72)	<0.001	
TBI (%)	25 (15.1)	62 (22.1)	1.60 (0.96-2.66)	0.071	
Tumor (%)	43 (25.9)	113 (40.2)	1.92 (1.26-2.93)	0.0022	
Others (%)	13 (7.8)	11 (3.9)	0.48 (0.21-1.10)	0.076	
Operation					
- Interval ≤1month (%)	8 (4.8)	77 (27.4)	7.50 (3.52–15.99)	<0.001	
Area of craniotomy ≥100 cm² (%)	41 (25.6)	93 (34.1)	1.50 (0.97-2.32)	0.067	
Operative time ≥10 hours (%)	14 (11.4)	31 (13.4)	1.21 (0.62–2.37)	0.58	
Location					
Fronto-temporal (%)	89 (53.0)	173 (61.8)	1.43 (0.97-2.11)	0.067	
Bifrontal (%)	46 (27.4)	35 (12.5)	0.38 (0.23-0.62)	<0.001	
Occipital or posterior fossa (%)	13 (7.7)	28 (10.0)	1.32 (0.67-2.63)	0.42	
Others (%)	20 (11.9)	44 (15.7)	1.38 (0.78–2.43)	0.26	
Devices					
Craniotomy					
Titanium plate (%)	131 (78.0)	197 (70.6)	0.68 (0.43-1.06)	0.088	
Absorbable plate (%)	10 (6.0)	17 (6.1)	1.03 (0.46-2.29)	0.95	
Cranioplasty					
Titanium mesh (%)*	41 (24.4)	44 (15.8)	0.58 (0.36–0.93)	0.024	
Ceramics (%)	4 (2.4)	22 (7.9)	3.51 (1.19–10.37)	0.016	
Hydroxyapatite (%)	2 (1.2)	16 (5.7)	5.05 (1.15-22.24)	0.018	
Polyethylene (%)	2 (1.2)	6 (2.2)	1.82 (0.36-9.14)	0.72	
Resin (%)	6 (3.6)	38 (13.6)	4.26 (1.76–10.30)	<0.001	
Artifacts					
Artificial dura (%)	18 (10.7)	80 (28.5)	3.31 (1.91–5.77)	<0.001	
Burr-hole cap (%)	9 (5.4)	3 (1.1)	0.19 (0.05-0.71)	0.012	
Cement paste (%)	9 (5.4)	17 (6.0)	1.14 (0.50–2.61)	0.76	
Factors associated with patients					
Aged (%)	25 (14.9)	35 (12.5)	0.81 (0.47–1.41)	0.46	
Cancer (%)	11 (6.5)	25 (8.9)	1.39 (0.67–2.91)	0.38	
DM (%)	8 (4.8)	21 (7.5)	1.62 (0.70-3.73)	0.26	
Thin skin (%)	89 (53.0)	61 (21.7)	0.25 (0.16–0.37)	<0.001	
Hyponutrition (%)	5 (3.0)	27 (9.6)	3.47 (1.31–9.18)	0.0082	
Malcirculation (%)	13 (7.7)	12 (4.3)	0.53 (0.24–1.19)	0.12	
Multiple surgeries (%)	35 (20.8)	94 (33.5)	1.91 (1.22–2.99)	0.0042	

Neurol Med Chir (Tokyo) 60, July, 2020

	Complications		Univariate	
Factors	Infection	Other		p value
	n = 168	n = 281	Odds ratio of infection	
Dirty wound (%)	4 (2.4)	23 (8.2)	3.66 (1.24–10.76)	0.012
Previous irradiation (%)	15 (8.9)	42 (14.9)	1.79 (0.96–3.34)	0.064
Sinusitis (%)	2 (1.2)	19 (6.8)	6.02 (1.39–26.18)	0.0068
Factors associated with surgeries				
Uncovered implant (%)	64 (38.1)	83 (29.5)	0.68 (0.46-1.02)	0.062
CSF leakage (%)	4 (2.4)	19 (6.8)	2.97 (0.99-8.89)	0.042
Skin ischemia (%)	4 (2.4)	6 (2.1)	0.89 (0.25-3.22)	1
Implant malfixation (%)	6 (3.6)	3 (1.1)	0.29 (0.072–1.18)	0.067
Ruptured suture (%)	5 (3.0)	26 (9.3)	3.32 (1.25-8.83)	0.011
Sinus maltreatment (%)	2 (1.2)	15 (5.3)	4.68 (1.06-20.73)	0.026
Factors associated with devices				
Device failure (%)	0 (0.0)	3 (1.1)	-	0.3

Table 2 (Continued)

*Titanium mesh was used both in *Craniotomy* and *Cranioplasty*. It is placed in *Cranioplasty* for certain reasons of data collection. CSF: cerebrospinal fluid, DM: diabetes mellitus, mRS: modified Rankin scale, TBI: traumatic brain injury.

national questionnaire survey has revealed a record high number of cases with complications. The calculated annual incidence of complications related to cranial implants is 0.558% per year. For craniotomy and cranioplasty, titanium plate and mesh were mainly used, respectively. Among 832 cases with complications reported by 183 institutes that responded to the primary survey, detailed data on 449 cases (54.0%) at 68 institutes (37.2%) were obtained in the second survey. Our questionnaire results shed light on various complications and have allowed us to identify risk factors for infection, including male sex, tumor as the initial disease, and usage of resin, ceramics, hydroxyapatite, and artificial dura. Hyponutrition, multiple surgeries, dirty wound, and sinusitis were patient-derived risk factors. CSF leakage, ruptured suture, and sinus maltreatment were surgery-derived risk factors. The multivariate analyses showed that male sex, tumor as initial disease, interval shorter than 1 month between initial surgery and complication, and usage of resin and artificial dura were risk factors for infection. The risk factors for hospital stay longer than 30 days were age at initial disease, male sex, mRS, interval shorter than 1 month between initial surgery and complication, craniotomy area more than 100 cm², operative time over 10 hours, usage of ceramics and/or artificial dura, multiple surgeries, dirty wound, ruptured suture, infection, presence of bacteria, presence of MRSA, and removal as treatment. The multivariate analyses showed that age at initial disease, male sex, mRS, interval shorter than 1 month between initial surgery and complication, craniotomy area more than 100 cm^2 , operative time over 10 hours, and usage of titanium plate, ceramics, and artificial dura were risk factors for hospital stay longer than 30 days.

Incidence and characteristics of complications related to cranial implants

The incidence of complications related to cranial implants has been explored in several studies. Several large neurosurgical centers in the United States have jointly released a report on complications related to craniotomy, in which, over 11 years from 1997 to 2007, surgery was required for post-operative infection in 0.5% of cases (82/16540 cranial surgeries).⁵⁾ In that study, brain tumor was the most frequent causative disease and MSSA was the most common offending organism. That study and ours have a great deal in common in terms of the incidence, causative disease, and offending organism.

In a study on 5361 prospectively evaluated neurosurgical procedures, the rate of subsequently cultureproven infection was 0.61%, although two-thirds of these procedures were spinal procedures.⁶⁾ In a single-institute retrospective investigation of the removal of titanium plates after craniotomy, over 3 years from 2014 to 2016, 1.6% (5/319) of patients who had undergone craniotomy later underwent removal of the plates because of pain and

Variables		Multivariate	
variables	Odds ratio	95% CI	p value
Patients' characteristics			
Age at the initial surgery ≥70 years	1.77	0.86 - 3.62	0.12
Male sex	2.5	1.38 - 4.52	0.0024
mRS 3–5	1.16	0.64 - 2.13	0.62
Disease			
Vascular	2.3	0.61 - 8.67	0.22
TBI	2.14	0.51 - 8.96	0.3
Tumor	3.99	1.10-14.52	0.036
Others	Ref	Ref	NA
Operation			
Interval ≤1month	15.2	5.27 - 43.8	<0.001
Area of craniotomy ≥100 cm²	0.89	0.45 - 1.77	0.74
Operative time ≥10 hours	1.78	0.77 - 4.12	0.18
Location			
Fronto-temporal	1.13	0.44 - 2.90	0.79
Bifrontal	0.53	0.20 - 1.44	0.22
Occipital or posterior fossa	1.37	0.43 - 4.32	0.59
Others	Ref	Ref	NA
Devices			
Craniotomy			
Titanium plate	0.77	0.34 - 1.77	0.54
Cranioplasty			
Titanium mesh*	0.6	0.29 - 1.25	0.18
Ceramics	6.8	1.32 - 35.05	0.022
Hydroxyapatite	4.1	0.47 - 36.09	0.2
Resin	6.9	1.45 - 32.84	0.015
Artifacts			
Artificial dura	2.28	1.10-4.75	0.027
Burr-hole cap	0.019	0.0014-0.25	0.0027

 Table 3
 Multivariate analysis for factors associated with infection

*Titanium mesh was used both in *Craniotomy* and *Cranioplasty*. It is placed in *Cranioplasty* for certain reasons of data collection. mRS: modified Rankin scale, TBI: traumatic brain injury.

protrusion, although this might be a relatively high incidence. $^{\scriptscriptstyle 7)}$

Studies specifically addressing complications after cranioplasty offer additional detailed information. The incidence of complications related to titanium mesh was reported at the relatively high rate of 29% among 127 cranioplasties in Western Australia.⁸⁾ Infection was the most frequent complication type with an incidence of 18%. Large titanium mesh was a significant risk factor for infection. Similar data have been reported in a study in England⁹⁾ in which the rates of complication and titanium plate removal were 26.4% and 10.3%, respectively. In 69% of cases with system removal, removal was indicated due to infection. The risk factors associated with complications were trauma as the initial disease and large skull defect (larger than 100 cm²).

In another study, 155 non-titanium cranioplasties performed between 2005 and 2016 at a single institute in Japan were retrospectively reviewed.¹⁰⁾ The overall complication rate was 12.3%. Infection was the most frequent complication, occurring at a rate

		ay longer than days	Univariate	
Factors	No	Yes	Odds ratio	p value
	n=287	n=154		
Patients' characteristics				
Age at the initial surgery ≤10 years (%)	11 (3.8)	6 (3.9)	1.02 (0.37-2.81)	1
Age at the initial surgery ≥70 years (%)	41 (14.3)	37 (24.0)	1.90 (1.16–3.12)	0.011
Male sex (%)	107 (37.5)	85 (55.2)	2.05 (1.38–3.05)	<0.001
mRS 3–5(%)	83 (29.3)	81 (53.6)	2.79 (1.85-4.20)	<0.001
Disease				
Vascular (%)	122 (42.5)	56 (36.8)	0.79 (0.53–1.18)	0.25
TBI (%)	49 (17.1)	35 (23.0)	1.45 (0.89–2.36)	0.13
Tumor (%)	100 (34.8)	53 (34.9)	1.00 (0.66–1.51)	1
Others (%)	16 (5.6)	8 (5.3)	0.94 (0.39–2.25)	0.89
Operation				
Interval ≤1month (%)	39 (13.6)	45 (29.2)	2.61 (1.61-4.24)	<0.001
Area of craniotomy ≥100 cm2 (%)	67 (24.3)	66 (44.0)	2.45 (1.60-3.74)	<0.001
Operative time ≥10 hours (%)	21 (9.9)	23 (17.0)	1.88 (0.99–3.55)	0.0496
Location				
Fronto-temporal (%)	158 (55.1)	100 (65.4)	1.54 (1.03–2.31)	0.037
Bifrontal (%)	58 (20.2)	22 (14.4)	0.66 (0.39–1.13)	0.13
Occipital or posterior fossa (%)	33 (11.5)	7 (4.6)	0.37 (0.16–0.86)	0.016
Others (%)	38 (13.2)	24 (15.7)	1.22 (0.70–2.12)	0.48
Devices				
Craniotomy				
Titanium plate (%)	216 (75.3)	108 (71.1)	0.81 (0.52–1.25)	0.34
Absorbable plate (%)	18 (6.3)	8 (5.3)	0.83 (0.35–1.96)	0.67
Cranioplasty				
Titanium mesh (%)*	61 (21.3)	22 (14.5)	0.63 (0.37–1.07)	0.084
Ceramics (%)	12 (4.2)	14 (9.2)	2.32 (1.05–5.16)	0.034
Hydroxyapatite (%)	12 (4.2)	6 (3.9)	0.94 (0.35–2.56)	0.91
Polyethylene (%)	5 (1.7)	2 (1.3)	0.75 (0.4–3.92)	1
Resin (%)	27 (9.4)	17 (11.2)	1.21 (0.64–2.30)	0.56
Artifacts				
Artificial dura (%)	41 (14.3)	56 (36.4)	3.43 (2.15–5.46)	<0.001
Burr-hole cap (%)	7 (2.4)	4 (2.6)	1.07 (0.31–3.70)	0.92
Cement paste (%)	15 (5.2)	11 (7.1)	1.39 (0.62–3.12)	0.42
Factors associated with patients (%)				
Aged (%)	38 (13.2)	21 (13.6)	1.03 (0.58–1.83)	0.91
Cancer (%)	20 (7.0)	16 (10.4)	1.55 (0.78–3.08)	0.21
DM (%)	18 (6.3)	11 (7.1)	1.15 (0.53–2.50)	0.73
Thin skin (%)	105 (36.6)	41 (26.6)	0.63 (0.41-0.97)	0.034

Table 4 Univariate analysis factors associated with hospital stay longer than 30 days

(Continued)

Table 4 (Continued)

		ay longer than days	Univariate		
Factors	No	Yes	Odds ratio	p value	
	n=287	n=154			
Hyponutrition (%)	15 (5.2)	15 (9.7)	1.96 (0.93–4.12)	0.073	
Malcirculation (%)	15 (5.2)	10 (6.5)	1.26 (0.55–2.87)	0.58	
Multiple surgeries (%)	68 (23.7)	59 (38.3)	2.00 (1.31–3.06)	0.0012	
Dirty wound (%)	12 (4.2)	14 (9.1)	2.29 (1.03-5.09)	0.037	
Previous irradiation (%)	36 (12.5)	21 (13.6)	1.10 (0.62–1.96)	0.74	
Sinusitis (%)	11 (3.8)	10 (6.5)	1.74 (0.72–4.20)	0.21	
Factors associated with operators					
Uncovered implant (%)	101 (35.2)	44 (28.6)	0.74 (0.48–1.13)	0.16	
CSF leakage (%)	13 (4.5)	10 (6.5)	1.46 (0.63–3.42)	0.38	
Skin ischemia (%)	5 (1.7)	5 (3.2)	1.89 (0.54–6.64)	0.31	
implant malfixation (%)	9 (3.1)	0 (0.0)	_	0.03	
Ruptured suture (%)	14 (4.9)	17 (11.0)	2.42 (1.16-5.05)	0.016	
Sinus maltreatment (%)	9 (3.1)	7 (4.5)	1.47 (0.54–4.03)	0.45	
Factors associated with devices					
Device failure (%)	2 (0.7)	1 (0.6)	0.93 (0.08–10.35)	1	
Types of complications					
Exposure (%)	131 (45.6)	21 (13.6)	0.19 (0.11–0.31)	<0.001	
Infection (%)	145 (50.5)	132 (85.7)	5.88 (3.54–9.76)	<0.001	
Bacterium positive (%)	97 (66.4)	103 (78.0)	1.79 (1.05–3.07)	0.032	
MRSA (%)	23 (15.8)	39 (29.5)	2.24 (1.25-4.01)	0.0058	
Multi-bacterium (%)	9 (6.2)	4 (3.0)	0.48 (0.14–1.58)	0.22	
Treatment					
Medication alone (%)	4 (1.4)	2 (1.3)	0.93 (0.17–5.16)	0.94	
With plastic surgery (%)	56 (19.5)	42 (27.3)	1.55 (0.98–2.45)	0.062	
Removal (%)	255 (89.2)	146 (95.4)	2.54 (1.09-5.90)	0.026	
Transplantation (%)	17 (5.9)	15 (9.8)	1.72 (0.83-3.55)	0.14	

*Titanium mesh was used both in *Craniotomy* and *Cranioplasty*. It is placed in *Cranioplasty* for certain reasons of data collection. CSF: cerebrospinal fluid, DM: diabetes mellitus, mRS: modified Rankin scale, TBI: traumatic brain injury.

of 8.4%, followed by postoperative epidural hemorrhage at 2.6% and ruptured suture at 1.3%. In that study, long operative time (over 98 minutes) was a significant risk factor for infection.

Several studies have reported on complication rates in pediatric cranioplasty. A multicenter retrospective study reported an infection rate of 10.5% in 359 pediatric patients.¹¹⁾ In a study on pediatric cranial reconstruction for craniosynostosis with resorbable plate system, the incidence of unplanned re-operation was 5.4%.¹²⁾ The relatively low incidences of complications in this study might be explained by the usage of a resorbable plate system and a procedure that does not involve dura opening.

Risk factors for infection after neurosurgical procedure

In our study, cases with complications were analyzed and risk factors for infection were explored. Male sex, brain tumor as the initial disease, cranioplasty with resin, combined usage of several artifacts (artificial dura, burr hole cap, and bone cement), CSF leakage, ruptured suture, sinus maltreatment, hyponutrition, multiple surgeries, dirty wound, and

Variables	Multivariate			
variables	Odds ratio	95% CI	p value	
Patients' characteristics				
Age at the initial surgery ≥70 years	2.01	1.02 - 3.99	0.044	
Male sex	2.91	1.64 - 5.17	<0.001	
mRS 3–5	2.06	1.17-3.63	0.013	
Disease				
Vascular	0.99	0.29-3.41	0.99	
TBI	0.49	0.13-1.81	0.28	
Tumor	0.62	0.18 - 2.09	0.44	
Others	Ref	Ref	NA	
Operation				
Interval ≤1month	3.22	1.69-6.12	<0.001	
Area of craniotomy $\geq 100 \text{ cm}^2$	1.94	1.03 - 3.64	0.04	
Operative time ≥10 hours	7.21	3-17.30	<0.001	
Location				
Fronto-temporal	0.53	0.22 - 1.26	0.15	
Bifrontal	0.52	0.2 - 1.39	0.19	
Occipital or posterior fossa	0.13	0.035-0.47	0.0018	
Others	Ref	Ref	NA	
Devices				
Craniotomy				
Titanium plate	1.26	0.64 - 2.50	0.04	
Cranioplasty				
Titanium mesh*	1.19	0.59 - 2.40	0.63	
Ceramics	4.05	1.32-12.47	0.015	
Artifacts				
Artificial dura	2.8	1.47 - 5.34	0.0017	

 Table 5
 Multivariate analysis for factors associated with hospital stay over 30 days

*Titanium mesh was used both in *Craniotomy* and *Cranioplasty*. It is placed in *Cranioplasty* for certain reasons of data collection. mRS: modified Rankin scale, TBI: traumatic brain injury.

sinusitis were the relevant risk factors. Cases with these risk factors should be handled with more cautions and steps should be taken to minimize the risks.

In several studies, large skull defect in cranioplasty was the risk factor for infection.^{5,6)} In our study, however, an area of craniotomy/cranioplasty over 100 cm² was not a significant risk factor. Similarly, long operative time was a significant risk factor in some studies,⁷⁾ although it was not significant in ours. The explanation for these discrepancies might lie in the fact that cases with craniotomy and cases with cranioplasty were analyzed together in our study. A retrospective study using data on 258 cranioplasties reported a complication rate of 10.9% (28/258 cases) and found that risk factors for infection were male sex, brain tumor, and surgery at the county hospital.¹³⁾ Similarly, in our study, male sex and brain tumor were considered the main risk factors for infection. Very recently, a multicenter retrospective study on autologous cranioplasty revealed that smoking and age less than 45 years were risk factors for complications requiring bone flap removal and that age less than 30 years was a risk factor for bone flap resorption.¹⁴⁾ In our study, we did not assess bone flap resorption because the aim was to assess complications related to cranial implants. As bone flap resorption does sometimes occur, however, its incidence and risk factors should be explored in the future.

Study limitations

This was a retrospective questionnaire-based study. The response rate in the primary survey was 30.6% (337/1103 institutes) and that in the second survey was 54.0% of cases with complications (449/832 patients). The response rates may be sufficiently high, yet the results of questionnaire surveys are not guaranteed to accurately represent all cases with complications.

Additionally, we reported the rates of complications related to cranial implants, including both craniotomy and cranioplasty. In our evaluation of the risk factors associated with infection, we only used the data on cases with complications. Our study therefore provides detailed information on cases with complications, but not cases without complications. This situation might limit the usefulness of risk factors for infection and long hospital stay. Although readers should consider these limitations, we believe that our data will be informative to neurosurgeons around the world.

Conclusions

Even after a long and uneventful postoperative period, complications related to cranial implants may arise after craniotomy/cranioplasty. The use of cranial implants is now common practice, but we still need to perform each neurosurgical procedure with care to minimize complications after surgery and keep the risk factors for complications in mind.

Acknowledgment

We would like to express our appreciation to all of the institutes that participated in this questionnaire survey:

Asahikawa Red Cross Hospital, Abashirinooka General Hospital, Ebetsu Hospital, Oji General Hospital, Otaru General Hospital, Sapporo Azabu Neurosurgical Hospital, Sapporo Medical University, Sapporo Teishinkai Hospital, Sunagawa City Medical Center, Muroran City General Hospital, Takikawa Neurosurgical Hospital, Nayoro City General Hospital, Hakodate Central General Hospital, Hokkaido University Hospital, Megumino Hospital, Rumoi Central Clinic, Aomori Prefectural Central Hospital, Akita Cerebrospinal and Cardiovascular Center, Akita Red Cross Hospital, Akita University Hospital, Iwaki City Medical Center, Iwate Medical University Hospital, Iwate Prefectural Kuji Hospital, Iwate Prefectural Iwai Hospital, Iwate Prefectural Kamaishi Hospital, Ohta Nishinouchi Hospital, Ohmagari Kousei Medical Center, Ogachi Central Hospital, Kohnan Hospital, Miyagi National Hospital,

Kakunodate General Hospital, Sendai East Neurosurgical Hospital, Southern Tohoku General Hospital, Tsuruoka Municipal Shonai Hospital, Tohoku University Hospital, Hachinohe City Hospital, Hirosaki University Hospital, Fukushima Medical University Hospital, Fukushima Red Cross Hospital, Hoshi General Hospital, Minamisoma Municipal General Hospital, South Miyagi Medical Center, Morioka Red Cross Hospital, Yamagata Prefectural Central Hospital, Yamagata University Hospital, Akiyama Neurosurgical Hospital, Atsugi City Hospital, Ayase Kousei Hospital, Isesaki-Sawa Medical Association Hospital, Itabashi Central General Hospital, Ushiku Aiwa General Hospital, Takasaki General Medical Center, NTT Medical Center Tokyo, Kasukabe Medical Center, Kasukabe Central General Hospital, Kameda Medical Center, Kawakita General Hospital, Kitasato University Medical Center, Kimitsu Chuo Hospital, Kyorin University Hospital, Kyowa Chuo Hospital, Kugayama Hospital, Kenou Tokorozawa Hospital, National Center of Neurology and Psychiatry, Saiseikai Utsunomiya Hospital, Saiseikai Kurihashi Hospital, Saiseikai Yokohamashi Tobu Hospital, Saitama Medical Center, Saitama Medical University Hospital, Saitama Cancer Center, Saitama Children's Medical Center, Saitama City Hospital, Saito Kinen Hospital, JA Toride Medical Center, Tokyo Yamate Medical Center, The Jikei University Kashiwa Hospital, Shiseikai Daini Hospital, Jichi Medical University, Juntendo University Hospital, Juntendo University Urayasu Hospital, Juntendo University Nerima Hospital, Juntendo Tokyo Koto Geriatric Medical Center, Shonan Kamakura General Hospital, Shin-Oyama City Hospital, St. Marianna Medical University Hospital, St. Marianna Medical University Toyoko Hospital, Seirei Yokohama Hospital, Soka Municipal Hospital, Moriya Daiichi General Hospital, Chiba Medical Center, Chiba Emergency Medical Center, Chiba Tokushukai Hospital, Tsukuba Memorial Hospital, Tsukuba Medical Center Hospital, Teikyo University Hospital, Teikyo University Medical Center, Tokai University Hospital, Tokyo Medical and Dental University Medical Hospital, Tokyo Dental College Ichikawa General Hospital, The Jikei University Hospital, Tokyo Women's Medical University Hospital, Tokyo Women's Medical University Yachiyo Medical Center, The University of Tokyo Hospital, Tokyo Metropolitan Hiroo Hospital, Tokyo Rosai Hospital, Toho University Medical Center Omori Hospital, Toho University Medical Center Ohashi Hospital, Toho University Medical Center Sakura Hospital, Tomei Atsugi Hospital, Dokkyo Medical University Saitama Medicacl Center, Toranomon Hospital, Nippon Medical School Hospital, Higashi Funabashi Hospital, Kurosawa Hospital, Hiratsuka Kyosai Hospital, Fukaya Red Cross Hospital, Furukawa Red Cross Hospital, Misyuku Hospital, Mito Medical Center, Mihara Memorial Hospital, Yamato Municipal Hospital, Yokohama Asahi Chuo General Hospital, Yokohama City University Medical Center, Yokohama City Stroke Neurospine Center, Yokohama Shintoshi Neurosurgical Hospital, Yokohama General Hospital, Aizawa Hospital, Aichi Prefectural Colony Central Hospital, Asahi University Hospital, Iida Municipal Hospital, NHO Shizuoka Institute of Epilepsy and Neurological Disorders, Kasugai Municipal Hospital, Kanazawa Medical University Hospital, Kanazawa University Hospital, Kanoiwa Hospital, Gifu Prefectural General Medical Hospital, Gifu University Hospital, Keiju Medical Center, Kofu Jonan Hospital, Kofu Neurosurgical Hospital, Noto General Hospital, Kobayashi Neurosurgical Hospital, Komaki City Hospital, Komatsu Municipal Hospital, Mishima General Hospital, Shizuoka Cancer Center, Shizuoka Children's Hospital, Shizuoka General Hospital, Shizuoka City ShizuokaHospital, Juntendo University Shizuoka Hospital, Showa Inan General Hospital, Shinshu University Hospital, Seirei Hamamatsu General Hospital, Seirei Mikatahara General Hospital, Takaoka City Hospital, Tachikawa General Hospital, Chuno Kosei Hospital, Toyamaken Saiseikai Toyama Hospital, Toyama University Hospital, Toyota Memorial Hospital, Nagaoka Red Cross Hospital, Shinonoi General Hospital, Nagano Red Cross Hospital, Nakamura Hospital, Nagoya City University, Nagoya Medical Center, Niigata Cancer Center Hospital, Niigata Prefectural Central Hospital, Niigata City General Hospital, Niigata University Hospital, Niigata Neurosurgical Hospital, Nishiniigata Chuo Hospital, Hamamatsu Medical Center, Fukui Prefectural Hospital, Fukui Red Cross Hospital, Fukui University Hospital, Fujita Health University Hospital, Hekinan Municipal Hospital, Murakami General Hospital, Meitetsu Hospital, Yamanashi Prefectural Central Hospital, Yamanashi Kosei Hospital, Yamanashi Red Cross Hospital, Yamanashi University Hospital, Ako City Hospital, Ako Central Hospital, Ishikiriseiki Hospital, Iseikai Hospital, Uji Tokushukai Medical Center, Omihachiman Community Medical Center, Osaka International Cancer Institute, Osaka City General Hospital, Osaka University Hospital, Osaka Saiseikai Izuo Hospital, Saiseikai Noe Hospital, Osaka Minami Medical Center, Osaka Rosai Hospital, Otemae Hospital, Okanami General Hospital, Kyoto University Hospital, Japanese Red Cross Kyoto Daini Hospital, University Hospital Kyoto Prefectural University of Medicine, Kyoto Yamashiro General Medical Center, Kindai University Nara Hospital, Kusatsu General Hospital, Goshi Hospital, Kouseikai Daiichi Hospital, Kobe City Medical Center General

Neurol Med Chir (Tokyo) 60, July, 2020

Hospital, Kobe University Hospital, Koto Memorial Hospital, Saiseikai Matsusaka General Hospital, Saiseikai Wakayama Hospital, Saso Hospital, Kobe Central Hospital, Hoshigaoka Medical Center, Shiga University of Medical Science Hospital, Junshin Hospital, Kishiwada City Hospital, Shinsuma Hospital, Suzuka Chuo General Hospital, Seikeikai Hospital, Takai Hospital, Takashima Municipal Hospital, Takatsuki General Hospital, Takarazuka City Hospital, Tesseikai Neurosurgical Hospital, Nara Prefecture General Medical Center, Nara Medical University Hospital, Nishinomiya Kyoritsu Neurosurgical Hospital, Nihonbashi Hospital, Baba Memorial Hospital, Hanna Central Hospital, Higashisumiyoshi Morimoto Hospital, Japanese Red Cross Society Himeji Hospital, Himeji Central Hospital, Hyogo Prefectural Awaji Medical Center, Bell Land General Hospital, Mie University Hospital, Mie Chuo Medical Center, Murata Hospital, Meijibashi Hospital, Moriguchi Ikuno Memorial Hospital, Yao Tokushukai General Hospital, Yagi Neurosurgical Hospital, Yamamoto Daisan Hospital, Shingu Municipal Medical Center, Wakayama Medical University Hospital, Wakayama Rosai Hospital, Uchida Neurosurgical Clinic, Ehime Prefectural Niihama Hospital, Ehime University Hospital, Okayama City Hospital, Okayama University Hospital, Okayama East Neurosurgical Clinic, Okayama Rosai Hospital, Onomichi Municipal Hospital, Kagawa University Hospital, Kajikawa Hospital, Kawasaki Medical School General Medical Center, Kochi Medical School Hospital, Saiseikai Matsuyama Hospital, Sadamoto Hospital, Sanuki Municipal Hospital, JA Onomichi General Hospital, Ritsurin Hospital, Shimonoseki Medical Center, Shimane Prefectural Central Hospital, Shimane University Hospital, Shuto General Hospital, Shunan Memorial Hospital, Hibino Hospital, Sumitomo Besshi Hospital, Takamatsu Red Cross Hospital, Tsuyama Chuo Hospital, Tokushima Prefecture Naruto Hospital, Tokushima Prefectural Central Hospital, Tokushima Red Cross Hospital, Tokushima University Hospital, Tottori Municipal Hospital, Tottori University Hospital, Hamada Medical Center, Hiroshima City Hiroshima Citizens Hospital, Fukuyama Medical Center, Fukuyama City Hospital, Fujisawa Neurosurgical Hospital, Matsuyama Shimin Hospital, Mine City Hospital, Yamaguchi Prefectural Grand Medical Center, Japanese Red Cross Yamaguchi Hospital, Yamaguchi University Hospital, Iizuka Hospital, Izumi General Medical Center, Imamura General Hospital, Imari Arita Kyoritsu Hospital, Urasoe General Hospital, Almeida Memorial Hospital, Tsurumi Hospital, Oita Prefectural Hospital, Ohama Daiichi Hospital, Omuta City Hospital, Nanbu Medical Center/Nanbu Child Medical Center, Ohara

Hospital, Kagoshima Medical Center, Kagoshima City Hospital, Kagoshima University Hospital, Kitakyushu City Yahata Hospital, Kitakyushu General Hospital, Kyushu University Hospital, Kyushu Central Hospital, Kumamoto University Hospital, Kurume University Hospital, Kokubu Neurosurgical Clinic, Kokura Memorial Hospital, Saiseikai Kumamoto Hospital, Saiseikai Hyuga Hospital, Saga University Hospital, Sasebo Chuo Hospital, Sato Daiichi Hospital, Hospital of the University of Occupational and Environmental Health, Shinbeppu Hospital, Nakagami Hospital, Nagasaki University Hospital, Nagasaki Rosai Hospital, Nagatomi Neurosurgical Hospital, Hachisuga Hospital, Saiseikai Futsukaichi Hospital, Fukuoka Shin Mizumaki Hospital, Fukuoka Seisyukai Hospital, Fukuoka Tokushukai Hospital, Fujimoto General Hospital, Beppu Medical Center, Miyazaki Prefectural Miyazaki Hospital, University of Miyazaki Hospital

Conflicts of Interest Disclosure

The authors have no COI to be declared related to this study.

References

- Smith SC, Pelofsky S: Adaptation of rigid fixation to cranial flap replacement. *Neurosurgery* 29: 417–418, 1991
- Yoshioka N, Tominaga S: Titanium mesh implant exposure due to pressure gradient fluctuation. World Neurosurg 119: e734–e739, 2018
- Takumi I, Akimoto M: One-stage reconstruction using a vascularized calvarial flap for intractable scalp ulcers in relation with cranial implants without removing the whole prosthesis. *Neurosurg Rev* 32: 363–368, discussion 368, 2009
- 4) Takumi I, Akimoto M, Hironaka K, et al.: Pedicle galeo-pericranial flap augmentation in salvage frontotemporal cranioplasty: additional 'neurosurgeonfriendly' reconstruction technique of aesthetic neurosurgery in superficial temporal artery branch compromised host. *Neurol Med Chir (Tokyo)* 58: 350-355, 2018

- 5) Dashti SR, Baharvahdat H, Spetzler RF, et al.: Operative intracranial infection following craniotomy. *Neurosurg Focus* 24: E10, 2008
- 6) Theodosopoulos PV, Ringer AJ, McPherson CM, et al.: Measuring surgical outcomes in neurosurgery: implementation, analysis, and auditing a prospective series of more than 5000 procedures. *J Neurosurg* 117: 947–954, 2012
- 7) Gupta R, Adeeb N, Griessenauer CJ, et al.: Removal of symptomatic titanium fixation plates after craniotomy. *Acta Neurochir (Wien)* 158: 1845–1848, 2016
- Wiggins A, Austerberry R, Morrison D, Ho KM, Honeybul S: Cranioplasty with custom-made titanium plates—14 years experience. *Neurosurgery* 72: 248–256, discussion 256, 2013
- 9) Mukherjee S, Thakur B, Haq I, Hettige S, Martin AJ: Complications of titanium cranioplasty—a retrospective analysis of 174 patients. *Acta Neurochir* (*Wien*) 156: 989–998, discussion 998, 2014
- 10) Shibahashi K, Hoda H, Takasu Y, Hanakawa K, Ide T, Hamabe Y: Cranioplasty outcomes and analysis of the factors influencing surgical site infection: a retrospective review of more than 10 years of institutional experience. *World Neurosurg* 101: 20–25, 2017
- 11) Rocque BG, Agee BS, Thompson EM, et al.: Complications following pediatric cranioplasty after decompressive craniectomy: a multicenter retrospective study. *J Neurosurg Pediatr* 22: 225–232, 2018
- 12) Branch LG, Crantford C, Cunningham T, et al.: Longterm outcomes of pediatric cranial reconstruction using resorbable plating systems for the treatment of craniosynostosis. *J Craniofac Surg* 28: 26–29, 2017
- 13) Klinger DR, Madden C, Beshay J, White J, Gambrell K, Rickert K: Autologous and acrylic cranioplasty: a review of 10 years and 258 cases. *World Neurosurg* 82: e525–530, 2014
- 14) Korhonen TK, Tetri S, Huttunen J, et al: Predictors of primary autograft cranioplasty survival and resorption after craniectomy. *J Neurosurg* 130: 1672–1679, 2019

Address reprint requests to: Takao Yasuhara, MD, PhD, Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, Okayama 700-8558, Japan. *e-mail*: tyasu37@cc.okayama-u.ac.jp